Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: Pooled analysis and clinical review

Expert Opinion on Drug Safety

Volumn 14, Issue 5, 2015, Pages 777-788

  Didier, Alain ^a   Bons, Brigitte ^b  

^a SERVICE DE PNEUMOLOGIE   (France)

^b Stallergenes SA   (France)

Author keywords

5 grass pollen tablet; Allergic rhinitis; Allergic rhinoconjunctivitis; Asthma; Clinical trial; Pollinosis; Safety; Sensitization; Sublingual immunotherapy; Tolerability

Indexed keywords

POLLEN EXTRACT;

ANAPHYLAXIS; ASTHMA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG MARKETING; DRUG MISUSE; DRUG SAFETY; DRUG SENSITIZATION; DRUG TOLERABILITY; EAR PRURITUS; EOSINOPHILIC ESOPHAGITIS; GRASS POLLEN; HUMAN; MOUTH EDEMA; OCULAR PRURITUS; ORAL PRURITUS; OROPHARYNX PAIN; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBLINGUAL IMMUNOTHERAPY; THROAT IRRITATION; TONGUE DISEASE; TONGUE PRURITUS; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; CHILD; CONJUNCTIVITIS, ALLERGIC; FEMALE; IMMUNOLOGY; MALE; META ANALYSIS; MIDDLE AGED; POACEAE; POLLEN; PRESCHOOL CHILD; PROCEDURES; RHINITIS, ALLERGIC; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, ALLERGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; POACEAE; POLLEN; RHINITIS, ALLERGIC; SUBLINGUAL IMMUNOTHERAPY; TIME FACTORS; YOUNG ADULT;

EID: 84928332723     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1017468     Document Type: Review

References (36)

1. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008;29:600-8
2. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11:471-6
3. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis 2012;6:11-23
4. EFA Book on Respiratory Allergies. Valovirta E. editor. 2011. Available from: http://www.theipcrg.org/download/attachments/689587/EFABookonRespiratoryAllergiesFINAL.pdf?version=1&modificationDate= 1332965739000 [Last accessed 2 April 2014]
5. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122(2 Suppl):S1-84
6. Uzzaman A, Story R. Chapter 5: allergic rhinitis. Allergy Asthma Proc 2012;33(Suppl 1):S15-18
7. WAO White Book on Allergy 2013 Update. Pawankar R, Holgate ST, Canonica GW, et al. editors. 2013. Available from: http://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf [Last accessed 23 February 2015]
8. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
9. Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician 2010;81:1440-6
10. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007(1):CD001936
11. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014;124:616-27
12. Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11
13. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6
14. Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131:1361-6
15. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:1-322
16. Didier A, Wahn U, Horak F, et al. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol 2014;10:1309-24
17. Summary of Product Characteristics: ® R R Oralair 100 I & 300 I sublingual tablets. Stallergènes SA, 2013. Available from: http://www.stallergenes.co.uk/fileadmin/images/corporate/gallery/Documents-pdf/2010-10-Oralair-fin-MRP-RCP.pdf [Last accessed 15 April 2014]
18. US Prescribing Information: Oralair (Sweet vernal, Orchard, Perennial rye, Timothy, and Kentucky blue grass mixed pollens allergen extract) Tablet for sublingual use. Stallergènes SA, 2014. Available from: http://oralair.com/docs/ORALAIR%20Prescribing% 20Information-Med%20Guide.pdf [Last accessed 11 May 2014]
19. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130:1327-34
20. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
21. Didier A, Malling HJ, Worm M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43:568-77
22. Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559-66
23. Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471-7
24. Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy-a Phase-1 study. Allergy 2006;61:1173-6
25. Study NCT00803244. Safety and efficacy of Phase III study on 300 IR SLIT in patients suffering from grass pollen rhinoconjunctivitis (with or without asthma). Stallergènes SA, 2011. Available from: http://clinicaltrials. gov/show/NCT00803244 [Last accessed 20 April 2014]
26. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6
27. Council for International Organizations of Medical Sciences (CIOMS) Working Group III. Guidelines for preparing core clinical safety information on drugs. Geneva, Switzerland: 1995
28. Wallerstedt SM, Brunlof G, Sundstrom A. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register. Drug Saf 2011;34:669-82
29. Epstein TG, Liss GM, Murphy-Berendts K, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract 2014;2:161-7
30. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7
31. Hsiao KC, Smart J. Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation. Pediatr Allergy Immunol 2014;25:714-5
32. Lyseng-Williamson KA. Sublingual five-grass pollen tablets (Oralair ): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. Drugs Ther Perspect 2014;doi:10.1007/s40267-40014-40131-40267
33. Makatsori M, Calderon MA. Anaphylaxis: still a ghost behind allergen immunotherapy. Curr Opin Allergy Clin Immunol 2014;14:316-22
34. Madsen F, Frolund L, Christensen M, et al. Quality assurance of allergen-specific immunotherapy during a national outbreak of anaphylaxis: results of a continuous sentinel event surveillance system. J Investig Allergol Clin Immunol 2009;19:253-9
35. Linneberg A, Jacobsen RK, Jespersen L, et al. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012;129:413-9
36. Linneberg A, Madsen F, Skaaby T. Allergen-specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol 2012;12:635-9